7 Sept 2026, 7:30 pmCompany Update
Proposal For Acquisition Of Up To 60% Equity Share Capital Of Meyonex Pharmaceuticals Limited,
General PDF
Sattva Sukun Lifecare Ltd operates in Distributors within the Consumer Discretionary sector.
475 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Consolidated figures
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Margins | |||||
| Gross margin % | 48.1% | 86% | 71% | 83.5% | -7.1% |
| EBITDA margin % | 6.5% | 44.3% | 54.1% | 61.8% | -15.9% |
| EBIT margin % | 2.6% | 34.4% | 43.4% | 53.8% | -17.6% |
| PAT margin % | 1.3% | 24.9% | 33.5% | 47.3% | 0.7% |
| Working capital | |||||
| Receivable days | — | 499 | 512 | 385 | 125 |
| Inventory days | — | 2,579 | 1,035 | 2,404 | 81 |
| Payable days | — | 412 | 181 | 529 | 581 |
| NWC days | — | 2,665 | 1,366 | 2,260 | -375 |
| Leverage | |||||
| Current ratio | — | 8 | 10.31 | 6.41 | 1.39 |
| Debt to EBITDA | — | 0.31 | 0.09 | 0.16 | — |
| Debt to equity | — | 0.02 | 0.01 | 0.02 | 0.08 |
| Interest coverage | 2 | — | 155 | 64.6 | 5.2 |
| Asset turnover | — | 0.14 | 0.15 | 0.2 | 0.29 |
| Return ratios | |||||
| Return on assets % | — | 3.4% | 5.1% | 9.4% | 0.2% |
| Return on capital employed % | — | 5% | 8.2% | 13.9% | 0.6% |
| Return on equity % | — | 3.6% | 5.4% | 10.4% | 0.5% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
No scheme among the 32 fund houses on record reported a position in Sattva Sukun Lifecare Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| M.K. Exim (India) LtdMKEXIMMKEXIM | ₹269 Cr | ₹269 Cr | ₹93 Cr | ₹23 Cr | 24.9% | ₹18 Cr | 19.2% | 26.7% | 19.2% | 213 |
| Khemani Distributors & Marketing LtdKDMLKDML | ₹261 Cr | — | ₹68 Cr | ₹-28 Cr | -41.8% | ₹-13 Cr | -19.1% | — | — | — |
| Ace Men Engg Works LtdACEMENACEMEN | ₹147 Cr | ₹147 Cr | ₹1 Cr | ₹0 Cr | — | ₹0 Cr | — | 0% | 0% | — |
| MRP Agro LtdMRPMRP | ₹103 Cr | — | ₹59 Cr | ₹5 Cr | 9.2% | ₹4 Cr | 6.8% | — | — | — |
| Sattva Sukun Lifecare LtdTAVEXIATAVEXIA | ₹45 Cr | ₹49 Cr | ₹32 Cr | ₹-5 Cr | -15.9% | ₹1 Cr | 0.7% | 0.6% | 0.6% | -375 |
| Kotia Enterprises LtdKELKEL | ₹18 Cr | ₹18 Cr | ₹0 Cr | ₹-0 Cr | 52.7% | ₹-0 Cr | -190.8% | 3.8% | -7.4% | 418 |
Documents link to external sources (exchange filings, company investor pages).
| Holder (%) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.01% | 4.01% | 3.11% | 3.11% | 3.11% | 3.63% | 3.62% | 3.62% | 6.4% | 6.4% | 6.39% | 6.39% | |
| FII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 95.99% | 95.99% | 96.89% | 96.89% | 96.89% | 96.37% | 96.38% | 96.38% | 93.6% | 93.6% | 93.61% | 93.61% | |
| No. of shareholders | — | — | — | — | — | — | — | — | 35,984 | 37,375 | 36,620 | 35,910 |
Promoter holding up 2.38 percentage points since Sep 2023.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 6 May 2026 | JEMISHKUMAR ODHAVJIBHAI GABANI | Bulk | BSE | Sell | 40,19,000 | ₹0.70 | ₹0.28 Cr |
| 6 May 2026 | RG TRADERS | Bulk | BSE | Buy | 21,11,809 | ₹0.70 | ₹0.15 Cr |
| 30 Apr 2026 | KANABAR PARAG SURESH | Bulk | BSE | Sell | 27,32,023 | ₹0.70 | ₹0.19 Cr |
| 30 Apr 2026 | RG TRADERS | Bulk | BSE | Buy | 27,05,635 | ₹0.70 | ₹0.19 Cr |
| 30 Apr 2026 | KUBER EQUITY SERVICES LLP | Bulk | BSE | Sell | 21,75,000 | ₹0.70 | ₹0.15 Cr |
| 24 Apr 2026 | KANABAR PARAG SURESH | Bulk | BSE | Sell | 38,00,000 | ₹0.70 | ₹0.27 Cr |
| 22 Apr 2026 | PRATEEK RAJESH GUPTA | Bulk | BSE | Sell | 19,99,980 | ₹0.70 | ₹0.14 Cr |
| 21 Apr 2026 | OMJAY JANI | Bulk | BSE | Sell | 65,00,000 | ₹0.71 | ₹0.46 Cr |
| 21 Apr 2026 | KRISHNA KUMAR GOYAL | Bulk | BSE | Buy | 50,00,000 | ₹0.71 | ₹0.36 Cr |
| 21 Apr 2026 | AARSHI MANISH MEHTA | Bulk | BSE | Sell | 35,92,877 | ₹0.71 | ₹0.26 Cr |
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Proposal For Acquisition Of Up To 60% Equity Share Capital Of Meyonex Pharmaceuticals Limited,
Appointment Of Director
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Board Meeting Outcome for Outcome Of Board Meeting
Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Board Meeting Intimation for Intimation Regarding Adjournment Of Board Meeting
Board Meeting Intimation for Meeting Of Board Of Directors Of Tavexia Lifecare Ltd Is Schedule To Be Held On Friday, 04Th September 2026 .
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
| 7 Sept 2026, 7:24 pm | Company Update Appointment of Statutory Auditor/s | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s |
| 7 Sept 2026, 7:20 pm | Board Meeting Outcome of Board Meeting | Board Meeting Outcome for Outcome Of Board Meeting |
| 7 Sept 2026, 6:17 pm | Company Update Resignation of Statutory Auditors | Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors |
| 7 Sept 2026, 11:31 am | Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 |
| 4 Sept 2026, 8:50 pm | Company Update Board Meeting Rescheduled | Board Meeting Intimation for Intimation Regarding Adjournment Of Board Meeting |
| 1 Sept 2026, 4:42 pm | Board Meeting | Board Meeting Intimation for Meeting Of Board Of Directors Of Tavexia Lifecare Ltd Is Schedule To Be Held On Friday, 04Th September 2026 . |
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| 2 | 2 | 4 | 5 | 32 | |
| COGS | 1 | 0 | 1 | 1 | 35 |
| Gross profit | 1 | 2 | 3 | 4 | -2 |
| 1 | 1 | 1 | 1 | 3 | |
| 0 | 1 | 2 | 3 | -5 | |
| OPM % | 6.5% | 44.3% | 54.1% | 61.8% | -15.9% |
| Depreciation | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 6 | |
| Profit before tax | 0 | 1 | 2 | 3 | 0 |
| Tax | 0 | 0 | 0 | 1 | -0 |
| Tax % | 33.3% | 27.6% | 22.2% | 21.9% | -31.3% |
| 0 | 1 | 1 | 2 | 0 | |
| PAT margin % | 1.3% | 24.9% | 33.5% | 47.3% | 0.7% |
| EPS (₹) | 0 | 0.3 | 0.5 | 0.1 | 0 |
| EPS adjusted (₹) | 0 | 0 | 0.1 | 0.1 | 0 |
| Annual report | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 3 | 8 | 12 | 19 | 38 |
| Reserves | — | 7 | 10 | 5 | 5 |
| Minority interest | — | — | — | — | 0 |
| — | 0 | 0 | 1 | 4 | |
| — | 1 | 1 | 2 | 64 | |
| Total equity & liabilities | — | 16 | 23 | 27 | 111 |
| 0 | 2 | 1 | 1 | 4 | |
| CWIP | — | 0 | 0 | — | — |
| Investments | — | 8 | 11 | 11 | 13 |
| — | 7 | 11 | 15 | 95 | |
| Total assets | — | 16 | 23 | 27 | 111 |
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| -1 | -1 | -3 | 1 | -14 | |
| 1 | -10 | -3 | -0 | -4 | |
| 0 | 11 | 5 | -0 | 19 | |
| Net cash flow | -0 | 0 | -0 | 0 | 1 |
| Free cash flow | -1 | -3 | -3 | 0 | -18 |
| CFO / Operating profit % | -920% | -150% | -140.6% | 16.3% | — |